Search Results

ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.

Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix.

Telix Pharmaceuticals Limited announces it has submitted a New Drug Application to the United States Food and Drug Administration for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging1 for prostate cancer.

QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).

Telix Pharmaceuticals Limited announces that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its American Depository Shares, representing the Company’s ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nasdaq Global Market under the symbol “TLX”.

Telix Pharmaceuticals Limited announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.

Telix Pharmaceuticals Limited announces that it has completed the submission of a Biologics License Application to the United States Food and Drug Administration for its investigational radiodiagnostic PET1 agent, TLX250-CDx, for the characterisation of renal masses as clear cell renal cell carcinoma.